rg-012
Nucleic acidexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2016 (NCT02855268)
Timeline
Indications
Studied for
Mechanism of action
- microRNA 21INHIBITOR
microRNA 21 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- rg-012
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03373786 | Phase 1 | Nov 27, 2017 | Regulus Therapeutics Inc. |
| NCT02855268 | Phase 2 | Aug 1, 2016 | Regulus Therapeutics Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Regulus Therapeutics Inc. | For profit | 2 | 2 | 2 | 2016 |
1 organizations
Page 1 / 1